Immunotherapy pollinosis in children significantly reduces the risk of developing asthma, say Danish researchers.
Specialists company ALK-Abello conducted a study involving 117 children suffering from seasonal allergic, better known as pollinosis or hay fever. All the children suffered allergic to birch pollen or flowering plants, which manifested itself attacks of sneezing, secretions from the nose, redness of eyes when inhaled pollen.
Within three years 64 children treated with specific immunotherapy, that is, injection or admission under the tongue of small doses of pollen allergy, in a normal situation, provoking them develop allergic reactions. Allergies gradually increased the dose and the body "used" to it, resulting in the weakening and gradual disappearance of symptoms. The other 53 children received placebo, or inactive substance.
Monitoring of the children lasted for seven years after the end of a three-year course of therapy. During this period, asthma emerged from the 24 children from a control group and 16 children who received immunotherapy. Thus, immunotherapy reduced the risk of developing asthma at 4.6 times, said study leader Lars Jacobsen.
The effect of immunotherapy in respect of the pollinoza (in particular freedom from asthma and eye Redness under the action of allergens) was quite persistent and maintained throughout the period of observation, also noted scientist.
"In this light, specific immunotherapy should be considered not only the first-line therapy in allergic rinokonyunktivite, but the secondary prevention of respiratory allergic diseases," - summed Jacobsen.
A detailed report on the results of the study was published in the journal Allergy.
- 0 ratings
